LifeScience Biologics

Innorna Secures FDA Clearance For First In Class mRNA Therapy IN026 In Refractory Gout

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...

 March 19, 2026 | News

Everest Medicines Eyes Strategic Asia Expansion With Proposed Hasten Singapore Acquisition

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

 March 19, 2026 | News

DNA Script Expands Global Reach Of SYNTAX Platform Through Strategic Distribution Partnerships

DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA,  announced it has signed distribution ag...

 March 19, 2026 | News

Samsung Bioepis And Sandoz Expand Global Biosimilar Alliance Across Five Assets

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and ...

 March 18, 2026 | News

Taiwan Bio And Terumo BCT Advance Automated Treg Manufacturing With Quantum Flex Platform

Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support&nb...

 March 19, 2026 | News

Eccogene Enrols First Patient In Phase 2a MIST Trial Combining ECC4703 With Semaglutide

-Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammat...

 March 18, 2026 | News

Australia Grants CTA For First In Human KMCAR T Cell Therapy Targeting Multiple Myeloma

Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...

 March 18, 2026 | News

Viva Biotech Advances ActRIIA Targeted Mini Binder Discovery With AI Driven Proteina Complexa Optimisation

Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...

 March 18, 2026 | News

Viva Biotech Advances ActRIIA Targeted Mini Binder Discovery With AI Driven Proteina Complexa Optimisation

Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...

 March 18, 2026 | News

Viva Biotech Advances ActRIIA Targeted Mini Binder Discovery With AI Driven Proteina Complexa Optimisation

Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical...

 March 18, 2026 | News

BioCina Advances RLS 2201 With CMC Programme To Enable Clinical Entry

BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry,...

 March 18, 2026 | News

Alebund Partners R1 Therapeutics To Advance AP306 Globally For CKD Related Hyperphosphatemia

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease...

 March 18, 2026 | News

Akeso Secures China IND Clearance For First In Class Trispecific Antibody AK150 Targeting Solid Tumours

Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...

 March 17, 2026 | News

Hong Kong Approves Ohtuvayre For COPD Maintenance Treatment Under 1 Plus Regulatory Pathway

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special...

 March 16, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close